Login
Navigate Fool.com
Will BMY beat
the market?
Community Rating: 4 Stars: Favorite

49.12 0.20 (0.41%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $49.11
Previous Close $48.92
Daily Range $49.07 - $49.57
52-Week Range $41.11 - $57.49
Market Cap $81.4B
P/E Ratio 28.28
Dividend (Yield) $1.44 (2.9%)
Ex-Dividend Date
Dividend Pay Date
07/01/14
08/01/14
Volume 5,015,923
Average Daily Volume 8,188,943
Current FY EPS $1.78

How do you think BMY
will perform against the market?

Top BMY Bull/Bear Pitches

 

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches here!

 

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches here!

News & Commentary Rss Feed

What You Need to Know About Johnson & Johnson's Best-Selling Drugs

Johnson & Johnson's new drugs are driving sales growth; but new competition from AbbVie and Bristol-Myers Squibb create risk.

Notable ETF Inflow Detected - IWB, AMGN, UNH, BMY

Should Roche Buy Exelixis?

A successful phase 3 study has started rumors that Roche may bid for Exelixis

Keep Calm and Carry On, J&J

Thanks to J&J's new drugs, the company's Q2 earnings were solid. But a jittery market focused on the bad news.

2 Reasons to Watch Bristol-Myers Squibb Co

Bristol-Myers Squibb is winning big in Japan, can they bring that success home?

1 Hidden Blockbuster Lurking in Merck's Pipeline?

Merck (MRK) is studying MK-1439 for use alongside Gilead's (GILD) blockbuster HIV drug Truvada.

Obamacare's Surprising HIV Drug Demand

The Affordable Care Act is increasing access to life saving HIV tests and drugs made by Gilead (GILD), Bristol-Myers Squibb (BMY), and Johnson & Johnson (JNJ).

Should Dividend Investors Keep or Eject Bristol-Myers Squibb Co?

World Cup mania and dividend stocks collide

This Week in Biotech: Anacor's FDA A-OK and AbbVie's Insatiable Urge to Buy Something

Anacor gets a key pipeline product approved, Bristol-Myers prepares for a landmark new drug filing, and AbbVie continues its never-ending quest to buy Shire.

1 Drug More Important to Gilead Than Sovaldi

Gilead's Truvada is reshaping HIV treatment globally and may present a bigger opportunity to Gilead than Sovaldi over time.

See More BMY News...

Sector

Healthcare

Industry

Drugs

Bristol-Myers Squibb Co. (BMY) Description

Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments. Website: http://www.bms.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks